A CASE OF DILATED CARDIOMYOPATHY IN A PATIENT TREATED FROM ACUTE LEUKEMIA
Abstract
A case of dilated cardiomyopathy in a patient treated from acute leukemia.
About the Authors
T. N. Panova
Астраханская государственная медицинская академия
Russian Federation
Russian Federation
L. V. Zaklyakova
Астраханская государственная медицинская академия
Russian Federation
Russian Federation
T. P. Kucherova
Астраханская государственная медицинская академия
Russian Federation
Russian Federation
L. V. Kuryanova
Астраханская государственная медицинская академия
Russian Federation
Russian Federation
S. V. Mayorova
Астраханская государственная медицинская академия
Russian Federation
Russian Federation
E. A. Uklistaya
Астраханская государственная медицинская академия
Russian Federation
Russian Federation
References
1. Гершанович М.Л. Осложнения прихимио игормонотерапии злокачественных опухолей. БПВ. М: Медицина; 1982.
2. Calzas J., Lianes P., Cortes Funes H. Heart pathology of extracardiac origin ( YII ). Heart and neoplasms. Rev.Esp.Cardiol. 1998; 51 (4): 314-331.
3. Cordioli E., Tondini C., Pizzi C., Massarelli G. Silent myocardial infarction in a patient treated with radiation therapy and polychemiotherapy for Hodgkinrs lymphoma. Cardiologia 1997; 42 (6): 635-638.
4. Ferrans V.J., Clark J.R., Zhang J.Y. et al. Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia 1997; 39 (10): 928-937.
5. Kakadekar F.H., Sandor G.G., Flyer C. et al. Differences in dose scheduling as a factor in the etiology of anthra-cycline-induced cardiotoxicity in Ewing sarcoma patients. Med. Pediatr. Oncol. 1997; 28 (1): 22-26.
6. Niitsu N., Kato M./ Shikoshi K., Umeda M. Doxorubicin-induced myocardial damage in elderly patients with hematologic malignancies. Hippon-Ronen-Igakkai-Zasshi 1997; 34 (1): 38-42.
7. Weiss M.A., Drullinsky P., Maslak H. et al. A phase I trial of a single high dose of idarubicin combined with high dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia. 1998; 12 (6): 865-868.
8. Jensen B.V., Nielsen S.L., Jensen T.S. Angiotensin converting enzyme inhibitor in treatment of epirubicin induced dilatated cardiomyopathy. Ugerskr.Laeger. 1997; 159(13): 1945-1949.
9. Takahashi S., Denvir M.A., Harder L. et al. Effects of in vitro and in vivo exposure to doxorubicin (adriamycine) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in «chemically-skinned» rabbit ventricular trabeculae. Jpn.J.Pharmacol. 1998; 76(4): 405-408.
10. Lihshultz S.E. Monitoring for anthracycline cardiotoxity. Pediatrics 1994; 93 (3): 433-437.
11. Lipshultz S.E., Colan S.D., Gelber R.D. et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N.Engl.J.Med. 1991; 324 (12): 808-815.
Review
For citations:
Panova T.N., Zaklyakova L.V., Kucherova T.P., Kuryanova L.V., Mayorova S.V., Uklistaya E.A. A CASE OF DILATED CARDIOMYOPATHY IN A PATIENT TREATED FROM ACUTE LEUKEMIA. Russian Journal of Cardiology. 2001;(4):71-73. (In Russ.)
Views:
350
Email this article 